Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 27Classical hematology 14Other hematologic neoplasm 10Genitourinary 10Lymphoid 4CNS 4Thoracic 3Plasma cell 3Other 2Myeloid 2Gynecologic 2Endocrine 2Sarcoma 1Head & Neck 1

Conditions

Neuroendocrine Tumors 532Pituitary Neoplasms 188Multiple Endocrine Neoplasia Type 1 187Thyroid Cancer, Papillary 178Pheochromocytoma 153Carcinoma, Neuroendocrine 140Thyroid Neoplasms 130Neoplasms 107Paraganglioma 99Carcinoid Tumor 99Adrenocortical Carcinoma 92Thyroid Carcinoma, Anaplastic 82Pancreatic Neoplasms 69Neoplasm Metastasis 67Insulinoma 61Adrenal Gland Neoplasms 61Carcinoma, Medullary 59Gastro-enteropancreatic neuroendocrine tumor 58Adenocarcinoma, Follicular 58Carcinoma, Non-Small-Cell Lung 57Breast Neoplasms 56Adenoma, Islet Cell 56Lung Neoplasms 50Sarcoma 49Colorectal Neoplasms 49Carcinoma, Renal Cell 49Melanoma 47Small Cell Lung Carcinoma 45Prostatic Neoplasms 44Head and Neck Neoplasms 43

Interventions

Tranexamic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hemorrhage × Endocrine × Clear all
NCT04863339 2022-04-05

Tranexamic Acid for Blood Loss Minimization in Endoscopic Pituitary Surgery

University of North Carolina, Chapel Hill

Phase 2 Withdrawn
Endocrine

Hemorrhage, Pituitary Neoplasms

NCT01891838 2016-10-31

Vent-Hyp

Hopital Foch

Phase NA Completed
101 enrolled
Endocrine

Hemorrhage, Pituitary Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡